Key facts
- This page summarizes Rupert Vessey's Form 4 filing for Generate Biomedicines, Inc. (GENB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Mar 2026, 18:09.
Rupert Vessey - 26 Feb 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)
- Reporting relationship
- Director
- Issuer ticker
- GENB
- Reported as of
- 26 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2026, 18:09:27 UTC
- Prior SEC filing
- 03 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Wolf, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Rupert Vessey filed Form 4 for Generate Biomedicines, Inc. (GENB) on 02 Mar 2026.
Change
- Previous filing in this sequence was filed on 03 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001677618
Primary reporting owner
Vessey Rupert
- Relationship
- Director
- Address
- GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE
- Signature
- /s/ Michael Wolf, Attorney-in-Fact
- Signature date
- 02 Mar 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GENB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +29,561
- Change %
- Price
- $0.000000
- Shares after
- 29,561
- Date
- 26 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 29,561
- Exercise price
- $16.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.